NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Jul 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
EXELON (rivastigmine) by Novartis is cholinesterase inhibitors [moa]. First approved in 2007.
Drug data last refreshed 8h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EXELON (rivastigmine) is a cholinesterase inhibitor administered as a transdermal extended-release film patch, approved by the FDA on July 6, 2007. It is indicated for the treatment of cognitive symptoms in Alzheimer's disease and Parkinson's disease dementia by inhibiting the breakdown of acetylcholine in the central nervous system. The transdermal delivery system provides sustained drug exposure and improved tolerability compared to oral formulations. EXELON represents a foundational symptomatic therapy in cognitive decline management, though disease-modifying agents are increasingly capturing market share.
$0.0BPart D
Mechanism of Action
Cholinesterase Inhibitors
Pharmacologic Class:
Cholinesterase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)
Started May 2023
48 enrolled
Healthy
A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.
Started Dec 2018
100 enrolled
Alzheimer's Disease
NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.
Started May 2016
118 enrolled
Mild to Moderate Alzheimer's Disease
16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients
Started Aug 2014
222 enrolled
Alzheimer's Disease
Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles
Started Feb 2014
70 enrolled
Alzheimer's Disease
Worked on EXELON at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.